文献速递银屑病与炎症性皮肤病

司库奇尤单抗治疗中重度掌跖银屑病2.5年持续疗效:GESTURE随机双盲安慰剂对照试验

Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2·5-year results from GESTURE, a randomized, double-blind, placebo-controlled trial.
PubMed 文献 · Br J Dermatol · 2019-12-15

BACKGROUND: Secukinumab has shown sustained efficacy and safety in several manifestations of psoriasis. OBJECTIVES: GESTURE investigated the long-term (2·5-year) safety and efficacy of 150 mg and 300 mg subcutaneous secukinumab in 205 patients with moderate-to-severe palmoplantar…

要点

  • 17%(300mg)与18%(150mg)患者手足功能无困难,安全性良好。

研究设计与样本

  • GESTURE为随机、双盲、安慰剂对照、多中心IIIb期试验,在15个国家开展,共纳入205例中重度掌跖银屑病患者。
  • 研究全长140周,包括筛查(最长4周)、治疗期1(16周)、治疗期2(116周)和治疗后随访(8周)。
  • 纳入标准为年龄≥18岁、中重度掌跖银屑病且掌跖外至少有一处斑块。

主要发现

  • 安全性特征良好。

临床怎么用

  • 对中重度掌跖银屑病患者,司库奇尤单抗150mg或300mg皮下注射可考虑用于长期治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Secukinumab has shown sustained efficacy and safety in several manifestations of psoriasis. OBJECTIVES: GESTURE investigated the long-term (2·5-year) safety and efficacy of 150 mg and 300 mg subcutaneous secukinumab in 205 patients with moderate-to-severe palmoplantar psoriasis. METHODS: GESTURE was a randomized, double-blind, placebo-controlled, multicentre, phase IIIb trial conducted across 15 countries. The study was 140 weeks long and consisted of four periods: screening (up to 4 weeks), treatment period 1 (16 weeks), treatment period 2 (116 weeks) and post-treatment follow-up (8 weeks). Eligible patients were aged ≥ 18 years with moderate-to-severe palmoplantar psoriasis and at least one plaque outside of the palms and soles. Efficacy was assessed via a palmoplantar Investigator's Global Assessment (ppIGA) and the palmoplantar Psoriasis Area and Severity Index (PASI). RESULTS: The primary end point, a ppIGA score of 0 or 1, was met at week 16. The effect was sustained over 2·5 years with 59% [95% confidence interval (CI) 43·5-74·1] and 53% (95% CI 35·1-69·6) of patients in the secukinumab 300 mg and 150 mg groups, respectively, achieving clear or almost clear palms and soles (ppIGA 0 or 1). At 2·5 years, the mean palmoplantar PASI percentage was reduced in both the secukinumab 300 mg group (-74·7%) and the secukinumab 150 mg group (-61·6%). A total of 17% (secukinumab 300 mg group) and 18% (secukinumab 150 mg group) of patients experienced no difficulty in hands and feet functionality, as indicated by the palmoplantar quality of life instrument overall scores. The safety profile was favourable. CONCLUSIONS: GESTURE revealed that secukinumab provides a strong and sustained response over 2·5 years in challenging-to-treat palmoplantar psoriasis.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Gottlieb AB, Kubanov A, van Doorn M, et al. Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2·5-year results from GESTURE, a randomized, double-blind, placebo-controlled trial. Br J Dermatol. 2019. PMID: 31286480. doi:10.1111/bjd.18331

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。